Burning Rock Biotech Limited

    Jurisdiction
    China
    ISIN
    US12233L2060 (BNR)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €62.13M
    Gross margin
    70.3%
    EBIT
    -€43.07M
    EBIT margin
    -69.3%
    Net income
    -€41.75M
    Net margin
    -67.2%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Products

    Product Revenue
    Service €290.74M 468.0%
    Product €225.08M 362.3%

    Earnings Calls

    Latest earnings call: May 29, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 32K $142.72K -600 Sell

    Add to watchlist

    Notifications